Metastatic Colorectal Cancer
Treatment Controversies in Metastatic Colorectal Cancer
Speakers: Wen Wee Ma, MBBS, Senior Associate Consultant, Medical Oncology
Joleen M. Hubbard, MD, Assistant Professor of Oncology
Duration: 60 minutes
Presented on: December 16, 2016
Wen Wee Ma, MBBS
Wen Wee Ma, MBBS
Senior Associate Consultant, Medical OncologyWen Wee Ma, MBBS, is a senior associate consultant in the Division of Medical Oncology at Mayo Clinic, Rochester, Minnesota. He is a board-certified medical oncologist with expertise in gastrointestinal oncology and developmental therapeutics. His research focuses on early phase anti-cancer drug development, and the application in gastrointestinal malignancies, including colorectal and pancreatic cancers. Prior to joining Mayo Clinic in 2016, he was an associate professor of oncology and directed the gastrointestinal cancers drug development program at Roswell Park Cancer Institute in Buffalo, New York. He has authored and co-authored over 50 publications, including those in high impact journals such as New England Journal of Medicine and Journal of Clinical Oncology.
Joleen M. Hubbard, MD
Joleen M. Hubbard, MD
Assistant Professor of OncologyJoleen M. Hubbard, MD, is assistant professor of medical oncology at Mayo Clinic in Rochester, Minnesota, where is also the chair of the Gastrointestinal Tumor Group Practice. She specializes in the treatment of gastrointestinal cancers, focusing on her area of clinical research, colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology, with a special interest in clinical and biologic markers of frailty. She is a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. She earned her MD from University of Minnesota Medical School.
METASTATIC COLORECTAL CANCER: DECODING COMPLEX TREATMENT ALGORITHMS THROUGH DEBATES AND CASES
Provided by the University of Nebraska Medical Center, Center for Continuing Education
ACKNOWLEDGEMENT This activity is supported by educational grants from Genentech, Inc., Taiho Oncology, Inc, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education. The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS Live Internet Activity The University of Nebraska Medical Center, Center for Continuing Education designates the live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER CREDITS American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of credit for completing this program.
DATE OF RELEASE/EXPIRATION Live Activity Friday, December 16, 2016, from 3:00 PM – 4:00 PM EST: Treatment Controversies in Metastatic Colorectal Cancer Tuesday, January 31, 2017, from 3:00 PM – 4:00 PM EST: Examining Clinical Cases in Metastatic Colorectal Cancer
Enduring Material The enduring material will be available from December 16, 2016 – July 31, 2017.
ACTIVITY DESCRIPTION Metastatic colorectal cancer (CRC) is the third most common malignancy in both men and women and the second leading cause of cancer mortality in the United States. Overall survival rates for patients with advanced CRC at 1 and 2 years have increased dramatically due to the development of new cytotoxic and targeted treatments in the past two decades. The proliferation of new treatments for advanced CRC have improved patient outcomes, but present clinicians with new challenges in selecting appropriate therapies based on patient- and disease-specific factors, including molecular testing and toxicities, as well as designing treatment plans based on the concept of continuum of care. Clinicians specializing in CRC will benefit from a debate session in this first part of a two-session series. Faculty will review the latest safety and efficacy data of available treatments, as well as, debate on the benefits and challenges faced in the first, second, and beyond lines for metastatic CRC. The aim of the program is to provide education on integrating effective treatment plans to personalize treatment for patients with metastatic CRC.
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:
• Examine the latest safety and efficacy data of available treatments in the first, second, and beyond lines for metastatic CRC • Compare the benefits and challenges among available CRC treatments in first-, second-, and third-line settings • Summarize the key results from the abstracts presented at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) • Select optimal treatment algorithms for patients with metastatic CRC • Appraise the emerging application of immunotherapy for metastatic CRC
INTENDED AUDIENCE This activity is intended for medical oncologists and other health care professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved or interested in the therapeutic management of patients with metastatic colorectal cancer (CRC).
ESTIMATED TIME TO COMPLETE This activity consists of two sessions, each of which should take approximately 1 hour to complete.
METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Presenters: Disclosures: Joleen Hubbard, MD
Research support (to Mayo Clinic): Boston Biomedical, Inc.; Merck; Genentech; Senhwa Biosciences, Inc. Advisory board: (honorarium to Mayo Clinic): Boehringer Ingelheim; Genentech
Wen Wee Ma, MBBS
Research support (to Mayo Clinic): Bayer
University of Nebraska Medical Center, Center for Continuing Education Lois Colburn, Executive Director Has nothing to disclose. Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose. University of Nebraska Medical Center, Peer Reviewer Lyudmyla Berim, MD Has nothing to disclose. PlatformQ Health Education, LLC Hamsa Jaganathan, PhD, Medical Director Has nothing to disclose. Karen Greb–Murphy, Program Manager Has nothing to disclose.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.
DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantors. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
CONTACT INFORMATION Accreditation Support: Please contact the University of Nebraska Medical Center, Center for Continuing Education at firstname.lastname@example.org or call 402-559-4152.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com